Apimeds Pharmaceuticals US, Inc.
APUS
$2.27
$0.4625.41%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.95M | 1.37M | 1.28M | 1.53M | 1.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.60M | 1.37M | 1.28M | 1.56M | 1.36M |
| Operating Income | -3.60M | -1.37M | -1.28M | -1.56M | -1.36M |
| Income Before Tax | -3.71M | -1.50M | -1.39M | -1.65M | -1.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.71 | -1.50 | -1.39 | -1.65 | -1.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.71M | -1.50M | -1.39M | -1.65M | -1.42M |
| EBIT | -3.60M | -1.37M | -1.28M | -1.56M | -1.36M |
| EBITDA | -2.66M | -- | -- | -- | -- |
| EPS Basic | -0.39 | -0.19 | -0.18 | -0.23 | -0.21 |
| Normalized Basic EPS | -0.24 | -0.12 | -0.11 | -0.14 | -0.13 |
| EPS Diluted | -0.39 | -0.19 | -0.18 | -0.23 | -0.21 |
| Normalized Diluted EPS | -0.24 | -0.12 | -0.11 | -0.14 | -0.13 |
| Average Basic Shares Outstanding | 34.08M | 31.62M | 31.62M | 30.08M | 26.51M |
| Average Diluted Shares Outstanding | 34.08M | 31.62M | 31.62M | 30.08M | 26.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |